Quantcast

Latest Non-steroidal anti-inflammatory drugs Stories

2010-06-17 15:59:08

Separate study reveals that early control of inflammation in patients with RA arthritis important in reducing cardiovascular risk The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein thought to be a regulator of cardiovascular function) as a robust, non-invasive predictor of cardiovascular (CV) risk in patients with arthritis taking cyclooxygenase inhibitors has been reinforced by the results of a multinational study presented today at EULAR 2010, the Annual Congress of...

2010-06-17 15:30:43

Four out of ten high-risk patients prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) also received appropriate measures to prevent upper-gastrointestinal (UGI) problems, but the remainder did not receive adequate protection, according to a study in the June issue of Alimentary Pharmacology and Therapeutics. Although the number of patients receiving preventative strategies increased five-fold over the 11-year period studied by researchers in The Netherlands, greater steps need to be...

2010-06-17 06:46:00

NEW YORK, June 17 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced that new data, published today by The Lancet, show that arthritis patients at increased gastrointestinal (GI) risk taking CELEBREX demonstrated a significantly lower incidence of the novel composite endpoint of clinically significant upper and lower GI events compared with patients taking diclofenac plus omeprazole. This difference was driven by clinically significant decreases in hemoglobin and/or hematocrit...

2010-06-16 13:16:27

Gels, creams and sprays containing painkillers such as ibuprofen, diclofenac, ketoprofen, and piroxicam are safe and effective treatments for local pain, according to Cochrane Researchers. A new systematic review they have conducted shows that topical non-steroidal anti-inflammatory drugs (NSAIDs) are more effective than placebos for treating short-term pain and have few side effects. Topical NSAIDs are usually applied as gels, creams or sprays, to the specific areas of the body where pain is...

2010-06-09 08:00:00

NORTHBROOK, Ill., June 9 /PRNewswire/ -- Horizon Pharma, Inc., today announced that data on its two lead product candidates, LODOTRA®, a circadian cytokine modulator and novel modified release, low-dose prednisone tablet, and DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, will be presented during the European League Against Rheumatism (EULAR) Annual Congress taking place in Rome, Italy,...

2010-06-08 07:00:00

BRIDGEWATER, N.J., June 8 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in New Jersey, announced today that CAMBIA(TM) (diclofenac potassium for oral solution) is now available in the United States for the acute treatment of migraine with or without aura. CAMBIA was approved by the U.S. Food and Drug Administration in June 2009. "The approval and subsequent commercialization of CAMBIA as a unique formulation of diclofenac...

2010-05-26 15:00:00

Lead Candidate, LT-NS001, Shows Evidence of Improved GI Safety for Arthritis Patients WALTHAM, Mass., May 26 /PRNewswire/ -- Logical Therapeutics, Inc., a private, clinical stage biopharmaceutical company, announced today it had closed on a $16.9 million Series C equity financing. The round was led by existing investor SV Life Sciences, and included Burrill & Company, Novo A/S and Novitas Capital. Logical Therapeutics is developing a family of new chemical entities using its...

2010-05-26 08:00:00

NORTHBROOK, Ill., May 26 /PRNewswire/ -- Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review. Horizon is...

2010-05-17 07:00:00

MENLO PARK, Calif., May 17 /PRNewswire/ -- ROXRO PHARMA, Inc. (www.roxropharma.com) announced today that the U.S. Food and Drug Administration (FDA) has approved SPRIX(TM) (ketorolac tromethamine) Nasal Spray, for the short-term (up to 5 days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level. SPRIX is a prescription intranasal formulation of the analgesic ketorolac, a non-steroidal anti-inflammatory drug (NSAID), designed to provide...

2010-05-10 07:00:00

NEWPORT, Ky., May 10 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, today announced that it has tightly focused the strategic direction for the company on the pain management market. The company plans to leverage its core expertise in the prescription pain category by developing a range of products that address both the acute and chronic pain prescription segments as well as the over-the-counter pain market. Xanodyne has nearly a...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related